Search Results

DiscGenics, Inc. today announced that Flagg Flanagan, Chief Executive Officer and Chairman of DiscGenics will present at Canaccord Genuity’s 2024 Musculoskeletal Conference.

DiscGenics, Inc. announced that Flagg Flanagan, Chief Executive Officer and Chairman of DiscGenics is presenting at Biotech Showcase 2024.

DiscGenics, Inc. announced that Flagg Flanagan, Chief Executive Officer and Chairman of DiscGenics will present at the following conferences.

DiscGenics, Inc. today announced that it will present at Canaccord Genuity’s 18th Annual Musculoskeletal Conference taking place in Las Vegas, NV on Tuesday, March 7, 2023.

DiscGenics, Inc. announced that it will be participating in the 41st Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA on January 9 – 12, 2023.

DiscGenics, Inc. today announced that Flagg Flanagan, Chief Executive Officer and Chairman will present virtually at the annual Cell & Gene Meeting on the Mesa to be held October 11-13 in Carlsbad, California and livestreamed globally.

DiscGenics, Inc. today announced the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Injectable Disc Cell Therapy (IDCT or rebonuputemcel), an injectable, allogeneic discogenic progenitor cell therapy for the treatment of symptomatic lumbar degenerative disc disease (DDD).

DiscGenics, Inc. today announced positive two-year clinical data from its first-in-human clinical study of IDCT (rebonuputemcel), an allogeneic discogenic progenitor cell therapy for lumbar degenerative disc disease (DDD).

DiscGenics, Inc. today announced that Matthew F. Gornet, MD, Board Certified Spine Surgeon at The Orthopedic Center of St. Louis, will present two-year follow-up data from the Company’s first-in-human clinical study of its allogeneic discogenic progenitor cell therapy (IDCT) for lumbar disc degeneration at the North American Spine Society (NASS) 37th Annual Meeting.